SWM
SRPT icon

SHP Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

SHP Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$762 Hold
35
– – ﹤0.01% 1530
2025
Q4 		$753 Buy
+35
New +$738 ﹤0.01% 1297

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SHP Wealth Management's SRPT Position: Q1 2026 in Review

SHP Wealth Management held its Sarepta Therapeutics (SRPT) position steady in Q1 2026 at 35 shares worth $762. The position accounts for ﹤0.01% of the portfolio, ranked #1530.

SHP Wealth Management first reported a position in SRPT in Q4 2025 and has held it in 2 quarters since. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • SHP Wealth Management held 35 shares of Sarepta Therapeutics worth $762 as of Q1 2026.
  • SHP Wealth Management left its Sarepta Therapeutics share count unchanged in Q1 2026.
  • Sarepta Therapeutics made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1530 holding.
  • SHP Wealth Management first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.